RxDoctor Payments Data

Kera Casber

Family · Ankeny, IANPI 1962958710

Payments from drug & device makers

$774in general payments, 2019–2025

Across 35 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$347
  • Boehringer Ingelheim$144
  • Novo Nordisk$121
  • Abbott$49
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$28
  • Lilly USA, LLC$27
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$75598%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$774 in reported general payments places this provider in the 75th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$22,152
Medicare patients
100
Services billed
535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$26,930
JardianceEmpagliflozin24$25,084
OzempicSemaglutide11$12,054
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,764
SynthroidLevothyroxine Sodium13$1,125
Levothyroxine Sodium79$758
Omeprazole58$667
Albuterol Sulfate HfaAlbuterol Sulfate23$650
Fenofibrate19$644
Rosuvastatin Calcium62$611
Baclofen18$587
Divalproex Sodium14$513
Gabapentin24$437
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$421
Atorvastatin Calcium123$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$27$26,93025 claims
Boehringer IngelheimJardiance$144$25,08424 claims
Novo NordiskOzempic$121$12,05411 claims
AbbVieSynthroid$347$1,12513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,268 family providers in Iowa.

Other family in Ankeny

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →